- Scott Gill, ISTO Technologies
- Idrasil, C3 International
- Martin Leblanc, Caprion
- Jeffrey Bacha, Del Mar
- Chris Jones, Glysure
- Vijay Aggarwal, The Channel Group
- Aftab Jamil, BDO
- Jack Young, Qualcomm Ventures
- Immune Pharmaceuticals and Epicept Corporation
- DARA BioSciences, Pt. II
- Intellicell BioSciences
- DARA Biosciences Pt. I
- HealthTech Capital
May 17 2013
On April 2nd, 2013, U.S. President Barack Obama unveiled the “BRAIN” Initiative, which is short for Brain Research through Advancing Innovative Neurotechnologies. The BRAIN Initiative may be known as the spiritual successor to the Human Genome Project, not only for its desire to understand a mysterious place known to medical science, but for taking its cues from the initial success of the HGP.
Bioinformatics Special Report, Part I: Where Does Biotechnology Data Come From?
May 16 2013
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting
April 30 2013
ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.
Release: Actium Biosystems Appoints Distinguished Pharmaceutical Scientist Dr. Jessie L.-S. Au to its Scientific Advisory Board
April 29 2013
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Partners & Sponsors